Drugs / SENEXIN B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03065010 | Nov 2016 → Mar 2018 | breast cancer | Biocad | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SENEXIN B | ChEMBL registry synonym — accepted as the source's own label CHEMBL4076837 ↗ |
| Known as | BCD-115 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03065010 ↗ |
| Action | Inhibit | “Inhibitor of CDK8/19” NCT03065010 ↗ |
| Modality | Small molecule | — CHEMBL4076837 ↗ |
| Route | Oral | “BCD-115 administered p.o. with intrapatient dose escalation” NCT03065010 ↗ |
| Target | CDK8 | “Inhibitor of CDK8/19” NCT03065010 ↗ |